Treatment with AZD1480 (a JAK1/JAK2 inhibitor) and ABT 317 (a JAK1-selective inhibitor) protected non-obese diabetic mice against autoimmune diabetes and reversed diabetes in newly diagnosed non-obese diabetic mice (16, 17). Here, JAK1 is linked to diabetes mellitus.